Sergio Fazio

Q: What Schools Are Affiliated With Sergio Fazio

Sergio Fazio is affiliated with the following schools: University of California, Berkeley, University of Alberta, Vanderbilt University, Stanford University, Bilkent University, Oregon Health & Science University

Sergio Fazio's AcademicInfluence.com Rankings

Sergio Fazio

Physics

#5315

World Rank

#7132

Historical Rank

physics Degrees

Download Badge

Physics

Sergio Fazio's Degrees

PhD Physics University of California, Berkeley
Masters Physics University of California, Berkeley
Bachelors Physics University of California, Berkeley

Why Is Sergio Fazio Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sergio Fazio's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) (1817)
Current perspectives on statins. (2000) (1213)
Low-density lipoproteins cause atherosclerotic cardiovascular disease (2018) (936)
Premature coronary-artery atherosclerosis in systemic lupus erythematosus. (2003) (886)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. (2017) (800)
Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis (2001) (657)
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 (2007) (636)
Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. (1999) (558)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) (541)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. (2016) (512)
Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation (1995) (471)
Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis (2009) (461)
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. (2011) (441)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial (2018) (378)
B-Lymphocyte Deficiency Increases Atherosclerosis in LDL Receptor–Null Mice (2002) (323)
Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice (2002) (301)
Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. (1997) (293)
Macrophages, inflammation, and atherosclerosis (2003) (278)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. (2018) (276)
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges (2012) (272)
Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. (2001) (250)
The relationship between dose of vitamin E and suppression of oxidative stress in humans. (2007) (242)
Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. (1999) (239)
Reduced Macrophage Apoptosis Is Associated With Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor–Null Mice (2004) (227)
Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. (2000) (226)
Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. (1994) (207)
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. (2001) (199)
Inactivation of Macrophage Scavenger Receptor Class B Type I Promotes Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice (2003) (197)
Metabolic syndrome and the risk of cardiovascular disease in older adults. (2006) (196)
Conditional Knockout of Macrophage PPARγ Increases Atherosclerosis in C57BL/6 and Low-Density Lipoprotein Receptor–Deficient Mice (2005) (190)
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. (2018) (183)
Combined Adipocyte-Macrophage Fatty Acid–Binding Protein Deficiency Improves Metabolism, Atherosclerosis, and Survival in Apolipoprotein E–Deficient Mice (2004) (182)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation (2013) (181)
Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease* (2010) (179)
Adipocyte Fatty Acid–Binding Protein, aP2, Alters Late Atherosclerotic Lesion Formation in Severe Hypercholesterolemia (2002) (172)
Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. (2012) (169)
Reduced Atherosclerotic Lesions in Mice Deficient for Total or Macrophage-Specific Expression of Scavenger Receptor-A (2000) (163)
Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis (2002) (161)
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. (2014) (155)
Macrophage Lipoprotein Lipase Promotes Foam Cell Formation and Atherosclerosis in Low Density Lipoprotein Receptor-deficient Mice* (2000) (150)
Deletion of Macrophage LDL Receptor–Related Protein Increases Atherogenesis in the Mouse (2007) (145)
PCSK9: From Basic Science Discoveries to Clinical Trials (2018) (141)
Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's Health Study. (2012) (139)
Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. (1994) (137)
Macrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation (2010) (135)
Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. (1994) (131)
Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. (2002) (130)
Mouse models of hyperlipidemia and atherosclerosis. (2001) (130)
Local effects of human PCSK9 on the atherosclerotic lesion (2016) (129)
The Evolving Future of PCSK9 Inhibitors. (2018) (126)
Cyclooxygenase-2 and inflammation in atherosclerosis. (2004) (126)
Are statins diabetogenic? (2011) (122)
Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. (2006) (121)
Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. (2012) (120)
Quantitative and Qualitative Differences in Proatherogenic NKT Cells in Apolipoprotein E–Deficient Mice (2004) (119)
Class A scavenger receptors, macrophages, and atherosclerosis (2001) (118)
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. (2010) (116)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms (2014) (115)
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy (2004) (113)
Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. (1999) (110)
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. (2005) (109)
Self-association of human PCSK9 correlates with its LDLR-degrading activity. (2008) (108)
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. (2016) (104)
Intra-individual Variation of Plasma Adipokine Levels and Utility of Single Measurement of These Biomarkers in Population-Based Studies (2007) (104)
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. (2016) (104)
Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. (1998) (101)
Macrophage Polarization by Angiotensin II-Type 1 Receptor Aggravates Renal Injury-Acceleration of Atherosclerosis (2011) (100)
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. (2008) (97)
Regulation of tumor necrosis factor receptor-1 and the IKK-NF-kappaB pathway by LDL receptor-related protein explains the antiinflammatory activity of this receptor. (2008) (96)
Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. (2008) (96)
PCSK9 Association With Lipoprotein(a). (2016) (96)
A practical approach to risk assessment to prevent coronary artery disease and its complications. (2003) (95)
Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. (1999) (92)
A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation* (1999) (91)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. (2017) (89)
Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. (2011) (89)
Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis[S] (2015) (87)
Retention of Low-Density Lipoprotein in Atherosclerotic Lesions of the Mouse: Evidence for a Role of Lipoprotein Lipase (2007) (86)
Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis (2013) (85)
The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. (1992) (85)
Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of 18 782 persons aged above 65 years in the Southern Community Cohort Study (2015) (85)
Nonpharmacologic treatment of dyslipidemia. (2009) (78)
Macrophage Expression of Peroxisome Proliferator–Activated Receptor-&agr; Reduces Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice (2007) (77)
Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. (2006) (77)
Tie1 attenuation reduces murine atherosclerosis in a dose-dependent and shear stress-specific manner. (2011) (76)
Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein* (2011) (75)
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. (2015) (74)
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol (2018) (74)
Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. (1993) (73)
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. (2020) (71)
Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) (71)
Low-Density Lipoprotein Receptor–Related Protein 1 Prevents Early Atherosclerosis by Limiting Lesional Apoptosis and Inflammatory Ly-6Chigh Monocytosis: Evidence That the Effects Are Not Apolipoprotein E Dependent (2011) (70)
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. (2016) (69)
Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. (1999) (68)
A Recycling Pathway for Resecretion of Internalized Apolipoprotein E in Liver Cells* (2001) (68)
Reduced ABCA1-Mediated Cholesterol Efflux and Accelerated Atherosclerosis in Apolipoprotein E–Deficient Mice Lacking Macrophage-Derived ACAT1 (2005) (67)
Factors Associated With the Prevalence of Hypertension in the Southeastern United States: Insights From 69 211 Blacks and Whites in the Southern Community Cohort Study (2014) (66)
Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol (2018) (66)
Atherosclerosis in chronic kidney disease: the role of macrophages (2011) (65)
Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages (2018) (64)
Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. (2011) (61)
Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. (1999) (60)
ACAT1 Deficiency Disrupts Cholesterol Efflux and Alters Cellular Morphology in Macrophages (2004) (59)
Dysfunctional high-density lipoproteins in children with chronic kidney disease. (2015) (58)
Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. (2006) (58)
Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice DOI 10.1194/jlr.M200108-JLR200 (2002) (58)
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease (2017) (57)
The PCSK9 revolution: Current status, controversies, and future directions. (2020) (57)
Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice[S] (2014) (56)
Recycling of Apolipoprotein E in Mouse Liver* (1999) (56)
PCSK9 and Atherosclerosis - Lipids and Beyond (2017) (54)
Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. (2008) (52)
A Pathway-Dependent on ApoE, ApoAI, and ABCA1 Determines Formation of Buoyant High-Density Lipoprotein by Macrophage Foam Cells (2007) (52)
Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. (2010) (52)
Angiotensin II Amplifies Macrophage-Driven Atherosclerosis (2004) (51)
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. (2016) (51)
Macrophage Mal1 Deficiency Suppresses Atherosclerosis in Low-Density Lipoprotein Receptor–Null Mice by Activating Peroxisome Proliferator-Activated Receptor-&ggr;–Regulated Genes (2011) (51)
Increased Cholesterol Efflux in Apolipoprotein AI (ApoAI)–Producing Macrophages as a Mechanism for Reduced Atherosclerosis in ApoAI(−/−) Mice (2001) (51)
Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. (2018) (50)
Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142). (1994) (50)
Cyclooxygenase-2 and atherosclerosis (2002) (50)
The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall. (2001) (48)
The Recycling of Apolipoprotein E in Primary Cultures of Mouse Hepatocytes (2003) (48)
Lifestyle determinants of C-reactive protein in middle-aged, urban Chinese men. (2012) (47)
Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk (2000) (47)
Lipoprotein Subclasses Determined by Nuclear Magnetic Resonance Spectroscopy and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis (2010) (46)
Retrovirus-mediated Expression of Apolipoprotein A-I in the Macrophage Protects against Atherosclerosis in Vivo * (2001) (46)
The cell biology and physiologic relevance of ApoE recycling. (2000) (45)
Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab (2019) (44)
Synthesis and secretion of apolipoprotein E occur independently of synthesis and secretion of apolipoprotein B-containing lipoproteins in HepG2 cells. (1992) (43)
Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus (2013) (43)
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. (2015) (42)
Application of PCSK9 Inhibitors in Practice: Part 2 The Patient Experience (2019) (42)
Rapid quantification of murine ABC mRNAs by real time reverse transcriptase-polymerase chain reaction Published, JLR Papers in Press, September 1, 2002. DOI 10.1194/jlr.D200020-JLR200 (2002) (41)
PMP22 Is Critical for Actin-Mediated Cellular Functions and for Establishing Lipid Rafts (2014) (41)
Failure of ACAT inhibition to retard atherosclerosis. (2006) (41)
DNA repair synthesis and DNA fragmentation in primary cultures of human and rat hepatocytes exposed to cyproterone acetate. (1995) (40)
The enhanced association of apolipoprotein E with apolipoprotein B-containing lipoproteins in serum-stimulated hepatocytes occurs intracellularly. (1995) (40)
Quantum dot mediated imaging of atherosclerosis (2009) (40)
Increased Cerebral Cortical Lipid Peroxidation and Abnormal Phospholipids in Aged Homozygous apoE-Deficient C57BL/6J Mice (1999) (39)
The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I. (2005) (38)
Acyl-coenzyme A:cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages Published, JLR Papers in Press, July 1, 2005. DOI 10.1194/jlr.M500101-JLR200 (2005) (38)
Cyclooxygenase-1 Deficiency in Bone Marrow Cells Increases Early Atherosclerosis in Apolipoprotein E– and Low-Density Lipoprotein Receptor–Null Mice (2005) (37)
Renal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1 (2009) (37)
Obesity and altered glucose metabolism impact HDL composition in CETP transgenic mice: a role for ovarian hormones[S] (2012) (37)
Loss of Macrophage Low-Density Lipoprotein Receptor–Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-&agr; Inhibition (2016) (37)
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. (2017) (36)
Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities (2017) (36)
Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI Published, JLR Papers in Press, February 13, 2007. (2007) (36)
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High‐Density Lipoprotein–Enriched Serum in Rheumatoid Arthritis (2016) (36)
Macrophage Apolipoprotein E Reduces Atherosclerosis and Prevents Premature Death in Apolipoprotein E and Scavenger Receptor–Class BI Double-Knockout Mice (2006) (36)
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. (2010) (36)
Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. (2011) (35)
Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. (2007) (35)
Hepatocyte-derived ApoE Is More Effective than Non-hepatocyte-derived ApoE in Remnant Lipoprotein Clearance* (2003) (35)
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. (2007) (34)
Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. (2006) (33)
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (2017) (33)
A form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene (1991) (33)
Altered lipoprotein metabolism in transgenic mice expressing low levels of a human receptor-binding-defective apolipoprotein E variant. (1994) (32)
ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects. (2005) (31)
Accumulation of human apolipoprotein-E in rat plasma after in vivo intramuscular injection of naked DNA. (1994) (31)
Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice (2016) (31)
Plasma lipid levels and colorectal adenoma risk (2015) (31)
Impaired Secretion of Apolipoprotein E2 from Macrophages* (2007) (31)
Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus (2008) (31)
Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo: bone marrow transplantation studies in the mouse. (1997) (30)
Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I Published, JLR Papers in Press, July 1, 2005. DOI 10.1194/jlr.M500181-JLR200 (2005) (30)
Insights into Atherosclerosis Using Nanotechnology (2010) (30)
Targeting PCSK9 for Therapeutic Gains (2015) (30)
Combined Vitamin C and Vitamin E Deficiency Worsens Early Atherosclerosis in Apolipoprotein E–Deficient Mice (2010) (30)
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. (2008) (30)
Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL[S] (2015) (29)
Macrophage IKK&agr; Deficiency Suppresses Akt Phosphorylation, Reduces Cell Survival, and Decreases Early Atherosclerosis (2016) (29)
Isoform-Specific Effects of Apolipoprotein E on Atherogenesis: Gene Transduction Studies in Mice (2001) (28)
Characterization of three mutations of the low density lipoprotein receptor gene in Italian patients with familial hypercholesterolemia. (1991) (28)
Macrophage apolipoprotein A-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters. (2003) (27)
Association of soy food intake with risk and biomarkers of coronary heart disease in Chinese men. (2014) (27)
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. (2019) (27)
Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real‐world evidence (2019) (27)
Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial (2012) (27)
Proatherogenic role for NK cells revealed. (2004) (27)
Mechanism of Down-regulation of RNA Polymerase III-transcribed Non-coding RNA Genes in Macrophages by Leishmania* (2010) (27)
Prevalence and determinants of metabolic syndrome according to three definitions in middle-aged Chinese men. (2009) (26)
The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment: evidence for multiple redundant pathways. (2004) (26)
Threshold Effects of Circulating Angiopoietin‐Like 3 Levels on Plasma Lipoproteins (2017) (26)
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. (2015) (26)
High-density lipoprotein therapeutics and cardiovascular prevention. (2010) (26)
Correlates of High Serum C-Reactive Protein Levels in a Socioeconomically Disadvantaged Population (2008) (25)
ACAT1 deficiency increases cholesterol synthesis in mouse peritoneal macrophages. (2006) (25)
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9 (2015) (25)
A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States (2013) (24)
Cyclooxygenase products and atherosclerosis. (2008) (24)
Evidence of metabolic syndrome in lean children with premature pubarche at diagnosis. (2008) (24)
Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis. (2011) (24)
Consuming a balanced high fat diet for 16 weeks improves body composition, inflammation and vascular function parameters in obese premenopausal women. (2014) (24)
Faculty Opinions recommendation of Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. (2020) (23)
Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma. (1993) (23)
Selective macrophage ascorbate deficiency suppresses early atherosclerosis. (2011) (23)
Oral retinoids and plasma lipids (2013) (22)
A neutral lipid-enriched diet improves myelination and alleviates peripheral nerve pathology in neuropathic mice (2019) (22)
Evaluation of macrophage-specific promoters using lentiviral delivery in mice (2011) (22)
Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. (2015) (22)
Murine bone marrow transplantation as a novel approach to studying the role of macrophages in lipoprotein metabolism and atherogenesis. (1996) (21)
Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia (2008) (21)
Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis (2008) (21)
Role of PAI-1 in hepatic steatosis and dyslipidemia (2021) (20)
Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome (2010) (19)
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low‐density lipoprotein receptor‐deficient mice (2021) (19)
PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux (2019) (19)
The Role of the Clinical Pharmacist in a Preventive Cardiology Practice (2019) (18)
Chylomicronemia syndrome: Familial or not? (2020) (17)
Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS. (1991) (17)
CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet (2018) (17)
HDL Particle Size and Functional Heterogeneity. (2016) (16)
ACAT inhibition: bad for macrophages, good for smooth muscle cells? (2005) (16)
Retroviral mediated expression of the human myeloid nuclear antigen in a null cell line upregulates Dlk1 expression (2002) (16)
Coronary Microvascular Dysfunction by Myocardial Contrast Echocardiography in Nonelderly Patients Referred for Computed Tomographic Coronary Angiography. (2019) (16)
Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells Published, JLR Papers in Press, March 13, 2006. (2006) (16)
Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin (2018) (15)
Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia. (2019) (15)
Uric acid correlates to oxidation and inflammation in opposite directions in women (2015) (15)
Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. (2016) (15)
Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism (2018) (15)
Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice. (2005) (14)
Angiotensin-Induced Abdominal Aortic Aneurysms in Hypercholesterolemic Mice: Role of Serum Cholesterol and Temporal Effects of Exposure (2014) (14)
Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma. (2009) (14)
Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. (2019) (14)
Unique pathway for cholesterol uptake in fat cells. (2004) (13)
Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein? (2003) (13)
High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke (2020) (13)
Sorting out the complexities of reverse cholesterol transport: CETP polymorphisms, HDL, and coronary disease. (2006) (13)
Reduced ABCA 1-Mediated Cholesterol Efflux and Accelerated Atherosclerosis in Apolipoprotein E – Deficient Mice Lacking Macrophage-Derived ACAT 1 (2005) (13)
Quantitative Estimates of the Variability of In Vivo Sonographic Measurements of the Mouse Aorta for Studies of Abdominal Aortic Aneurysms and Related Arterial Diseases (2011) (13)
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. (2020) (12)
Physiological relevance of apolipoprotein E recycling: studies in primary mouse hepatocytes. (2005) (12)
Carotid Adventitial Vasa Vasorum and Intima‐Media Thickness in a Primary Prevention Population (2015) (12)
ApoA-IV is secreted on discrete HDL particles by the rat hepatoma cell line McA-RH7777 transfected with ApoA-IV cDNA. (1993) (11)
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients (2020) (11)
Lack of association between arterial blood pressure and erythrocyte fatty acid composition in an Italian population sample. (1987) (11)
Putting Pleiotropy and Selection Into Context Defines a New Paradigm for Interpreting Genetic Data (2013) (11)
Setting the Agenda for Preventive Cardiology (2017) (11)
Presentation of the Rifle Project Risk-Factors and Life Expectancy (1993) (11)
Importance of high-density lipoprotein quality: evidence from chronic kidney disease (2013) (11)
Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study. (2015) (11)
Brief Commentary: Marijuana and Cardiovascular DiseaseWhat Should We Tell Patients? (2019) (10)
Evidence-based Management of Lipid Disorders (2011) (10)
More Clinical Lessons from the FIELD Study (2009) (10)
Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort. (2019) (10)
Identification of Small Proline-Rich Repeat Protein 3 as a Novel Atheroprotective Factor That Promotes Adaptive Akt Signaling in Vascular Smooth Muscle Cells (2014) (10)
Stability and Reliability of Plasma Level of Lipid Biomarkers and Their Correlation with Dietary Fat Intake (2008) (10)
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol (2020) (9)
Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low" (2001) (9)
PCSK 9 Association With Lipoprotein ( a ) (2016) (9)
Elevated lipoprotein(a) levels lower ABCA1 cholesterol efflux capacity. (2019) (9)
Recent insights into the pathogenesis of type III hyperlipoproteinemia. (1993) (9)
Interplay between apolipoprotein E and scavenger receptor class B type I controls coronary atherosclerosis and lifespan in the mouse. (2005) (9)
Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. (2021) (9)
Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion. (2013) (9)
The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe. (2015) (9)
Benzo[a]pyrene Potentiates the Pathogenesis of Abdominal Aortic Aneurysms in Apolipoprotein E Knockout Mice (2012) (9)
Sex-Specific Parental Effects on Offspring Lipid Levels (2015) (8)
Subcellular diversion of cholesterol by gain‐ and loss‐of‐function mutations in PMP22 (2020) (8)
A case of severe acquired hypertriglyceridemia in a 7-year-old girl. (2017) (8)
Comparison of Medical Care Utilization and Costs Among Patients With Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia. (2018) (7)
Co-expression of cholesteryl ester transfer protein and defective apolipoprotein E in transgenic mice alters plasma cholesterol distribution. Implications for the pathogenesis of type III hyperlipoproteinemia. (1994) (7)
Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice[S] (2014) (7)
Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis (DOI:10.1016/j.cmet.2006.02.010) (2006) (7)
Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. (2020) (7)
Real-world utilization of bempedoic acid in an academic preventive cardiology practice (2021) (7)
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies (2021) (7)
Exercise is Associated With Increased Small HDL Particle Concentration and Decreased Vascular Stiffness in Rheumatoid Arthritis (2018) (6)
Incident diabetes and statins: the blemish of an undisputed heavy weight champion? (2013) (6)
The role of statin therapy in primary hyperlipidemia and mixed dyslipidemia (2011) (6)
Abstract 15960: Macrophage IKKalpha Deficiency Suppresses Akt Phosphorylation, Reduces Cell Survival and Decreases Early Atherosclerosis (2013) (6)
Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin. (2012) (6)
Familial hypercholesterolemia related admission for acute coronary syndrome in the United States: Incidence, predictors, and outcomes. (2021) (5)
Insights on the kinetics and dynamics of the furin-cleaved form of PCSK9. (2020) (5)
Fenofibrate and risk of minor amputations in diabetes (2009) (5)
Faculty Opinions recommendation of Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. (2018) (5)
Fibrates – The Other Life-saving Lipid Drugs (2005) (5)
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9 (2020) (5)
Macrophage LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Is Required for the Effect of CD47 Blockade on Efferocytosis and Atherogenesis—Brief Report (2021) (5)
Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. (2022) (5)
Balanced high fat diet reduces cardiovascular risk in obese women although changes in adipose tissue, lipoproteins, and insulin resistance differ by race. (2018) (5)
High triglyceride to HDL cholesterol ratio is associated with increased coronary heart disease among White but not Black adults (2021) (5)
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. (2019) (5)
Preventive cardiology as a dedicated clinical service: The past, the present, and the (Magnificent) future (2020) (4)
Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice (2021) (4)
PCSK 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title : (2014) (4)
Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update (2022) (4)
Multi-centre study on completeness of urine collection in 11 European centres (1986) (4)
When it looks like familial hypercholesterolemia...but is not. (2012) (4)
Biologic bases of residual risk of cardiovascular events: A flawed concept (2018) (4)
Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome. (2012) (4)
Low levels of high-density lipoprotein cholesterol due to lecithin:cholesterol acyltransferase mutations increase carotid atherosclerosis. (2011) (4)
Familial Hypercholesterolemia: Genes and Beyond (2000) (4)
Plasma Lipidomic Patterns in Patients with Symptomatic Coronary Microvascular Dysfunction (2021) (4)
PREVENTIVE CARDIOLOGY AS NEW SUBSPECIALTY OF CARDIOVASCULAR MEDICINE. (2020) (3)
"Taking a look under the hood"-imaging the phenotypic heterogeneity of familial hypercholesterolemia. (2018) (3)
LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INCIDENT CORONARY HEART DISEASE AMONG WHITES IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY (2016) (3)
Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches (2021) (3)
PCSK9, a novel target for lowering LDL cholesterol: promise and progress (2012) (3)
Application of PCSK 9 Inhibitors in Practice Challenges and Opportunities (2017) (3)
On the relationship between cholesterol lowering and coronary disease event rate. (1998) (3)
Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. (2018) (3)
Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement (2021) (3)
Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1 (2021) (3)
Macrophage Lipoprotein Lipase Promotes Foam Cell Formation and Atherosclerosis in LDL receptor Deficient Mice (2000) (2)
Medication‐based versus target‐based lipid management (2018) (2)
Acyl-CoA : Cholesterol Acyltransferase Promotes Oxidized LDL / Oxysterol-Induced Apoptosis in Macrophages (2005) (2)
Familial Hypercholesterolemia: Use of Registries, Biobanks, and Cohort Studies To Improve its Diagnosis and Management in Non-Western Populations (2018) (2)
Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot. (2014) (2)
Lipoprotein(a) (2020) (2)
Aborted Sudden Cardiac Death in Young Man with Familial Hypercholesterolemia: A Case Report and Review of The Literature (2018) (2)
CHAPTER 2 – Regulation and Clearance of Apolipoprotein B–Containing Lipoproteins (2009) (2)
Loss of SPRR3 in ApoE-/- mice leads to atheroma vulnerability through Akt dependent and independent effects in VSMCs (2017) (2)
Short-term treatment with a lipid-lowering agent: Diethylaminoethyldextran (Dexide). Excretion of bile acids, neutral sterols and faecal fats (1982) (2)
Serum PCSK9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation (2013) (2)
Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia. (2020) (2)
PCSK9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title: Rashid et al.; PCSK9 Promotes Intestinal ApoB Overproduction (2014) (2)
The recycling of apolipoprotein E in macrophages Published, JLR Papers in Press, April 1, 2005. DOI 10.1194/jlr.M400418-JLR200 (2005) (2)
Abstract P044: Alcohol Consumption, Statin Use and Risk of All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort (2015) (1)
Increased Cardiovascular Risk in Patients with Diabetes, Statin-Controlled LDL Cholesterol, and Residual Hypertriglyceridemia (2018) (1)
Is it Time to Enhance Assessment of Alcohol Intake in Patients Slated for Statin Therapy? (2014) (1)
Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease. (2022) (1)
Dyslipidemias in children. (2012) (1)
The link between lipids, statins and cancer: is there a role for cardio-oncology? (2015) (1)
A new age of discovery for plasma lipoproteins. (2007) (1)
Abstract 19083: Macrophage Expression of Pcsk9 Influences Atherosclerosis Development (2013) (1)
82 COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LDL-C, NON-HDL-C AND APOB LEVELS IN HYPERLIPIDEMIC PATIENTS (2011) (1)
Withdrawn: "Taking a look under the hood"-Imaging the phenotypic heterogeneity of familial hypercholesterolemia. (2018) (1)
PCSK9 promotes intestinal overproduction of apolipoprotein-b lipoproteins through ldl-receptor dependent and independent mechanisms (2014) (1)
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial (2022) (1)
[Effects of the integration of a habitual diet with glucomannan fiber in hypercholesterolemia. A clinical study in familial and sporadic hyperlipoproteinemia with lipo-proteic phenotype IIa and IIb]. (1986) (1)
Genetic Disorders of HDL Metabolism (2015) (1)
Dyslipidaemia: The PCSK9 adventure — humanizing extreme LDL lowering (2017) (1)
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial (2023) (1)
59 RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NONHDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN (2011) (1)
Faculty Opinions recommendation of Safety and efficacy of bempedoic acid to reduce LDL cholesterol. (2019) (1)
Apolipoprotein E and Reverse Cholesterol Transport: The Role of Recycling in Plasma and Intracellular Lipid Trafficking (2007) (1)
DOES LOW HDL-C INCREASE CHD RISK WHEN TG & LDL-C ARE NORMAL? THE FRAMINGHAM OFFSPRING STUDY (2014) (1)
Unmet Needs in Understanding Lipoprotein(a) Pathophysiology: NHLBI Working Group Recommendations to Reduce Risk of Cardiovascular Disease and Aortic Stenosis (2018) (1)
Association-of-Serum-Selenium-with-Selected-Cardiovascular-Risk-Factors 1995 Microchemical-Journal (1995) (1)
activity of this receptor related protein explains the antiinflammatory − pathway by LDL receptor B κ Regulation of tumor necrosis factor receptor-1 and the IKK (2008) (1)
The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M400104-JLR200 (2004) (1)
PREDICTING HYPERTRIGLYCERIDEMIC PANCREATITIS - NOT SO FAST! (2018) (1)
Long-term Effect of Triple Combination Ezetimibe/Simvastatin+Extended-Release Niacin on Cholesterol Content of Lipoprotein Subclasses in Hyperlipidemic Patients (2009) (1)
Abstract 4: Deletion of Macrophage Low-density Lipoprotein Receptor-related Protein 1 (LRP1) Accelerates Atherosclerosis Regression by Increasing CCR7-dependent Egress of Plaque Macrophages (2017) (1)
Faculty Opinions recommendation of Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. (2017) (0)
The Potential of Electronic Health Record Data to Optimize Recruitment Efficiency in Cardiovascular Outcome Trials (2017) (0)
Faculty Opinions recommendation of Cardiovascular events in patients under age fifty with early findings of elevated lipid and glucose levels - The AMORIS study. (2018) (0)
Faculty Opinions recommendation of Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. (2018) (0)
Faculty Opinions recommendation of Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. (2019) (0)
Abstract 16265: Acute Coronary Syndrome in Patients With Familial Hypercholesterolemia: Incidence, Predictors, and Outcomes (2020) (0)
Abstract: P1443 LONG-TERM EFFECT OF COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN (E/S+N) ON LIPOPROTEIN SUBCLASSES IN PATIENTS WITH HYPERLIPIDEMIA (HL) (2009) (0)
Faculty Opinions recommendation of Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. (2019) (0)
Faculty Opinions recommendation of Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. (2016) (0)
Abstract 033: Differential Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Production and Function on Microsomal Triglyceride Transfer Protein (2018) (0)
0156 Both Circadian Clock And Sleep Control Plasma Levels Of Pcsk9, The Main Regulator Of Plasma Ldl Cholesterol (2019) (0)
Abstract 198: HDL Function and Genetic Regulation in a Nonhuman Primate Model of HDL Cholesterol Extremes (2016) (0)
Faculty Opinions recommendation of Repositioning of the Global Epicentre of Non-Optimal Cholesterol. (2020) (0)
Faculty Opinions recommendation of Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol. (2019) (0)
Abstract 282: Pattern of Development of Abdominal Aortic Aneurysms Induced by Angiotensin In Hypercholesterolemic Mice (2013) (0)
Abstract: 1006 EZETIMIBE/SIMVATASTATIN (E/S) PLUS EXTENDED RELEASE NIACIN (N) IN HYPERLIPIDEMIA (HL) PATIENTS WITH DIABETES (DM) OR METABOLIC SYNDROME (MS) (2009) (0)
Abstract 434: LDL Apheresis Significantly Alters HDL Cargo and Function in Familial Hypercholesterolemia Subjects (2014) (0)
Abstract 561: Reduced Serum Efflux Capacity Associates With Elevated Plasma Lp(a) Levels (2018) (0)
Binding of PCSK9 to circulating LDL: Effect of PCSK9 monoclonal antibodies on the LDL-bound PCSK9? (2018) (0)
Association between Plasma PCSK9 levels and Presence of Coronary Artery Calcium (2020) (0)
Faculty Opinions recommendation of Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. (2019) (0)
DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, CARDIOVASCULAR, AND CANCER CENTER 2013-2014 SEMINAR SCHEDULE* Please obtain prior approval when inviting a guest speaker from Dr. Di Cera. DATE SPEAKER HOST (2014) (0)
Abstract 29: Novel Atheroma-specific Atheroprotective Factor Promotes VSMC Pro-survival Signaling (2014) (0)
Faculty Opinions recommendation of Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. (2018) (0)
Abstract 565: Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression (2018) (0)
COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED-RELEASE NIACIN THERAPY IMPROVES ATTAINMENT OF RECOMMENDED LEVELS OF LDL-C, NON-HDL-C AND APO B IN HYPERLIPIDEMIC PATIENTS (2011) (0)
Abstract 156: Macrophage Low-Density Receptor--Related Protein 1 Deficiency Facilitates Atherosclerosis Regression in Hyperlipidemic Mice (2014) (0)
Response by Mueller et al to Letter Regarding Article, "Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages". (2019) (0)
Faculty Opinions recommendation of PCSK9 inhibition with alirocumab reduces lipoprotein (a) levels in non-human primates by lowering apolipoprotein (a) production rate. (2018) (0)
Abstract 240: Serum Cholesterol and Angiotensin-Induced Abdominal Aortic Aneurysm in Hypercholesterolemic Mice (2013) (0)
Faculty Opinions recommendation of Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study. (2018) (0)
Abstract 276: SR-BI Suppresses Apoptosis by Reducing Endoplasmic Reticulum Stress and Promoting Akt Activity in Macrophages (2014) (0)
HIGH HDL CHOLESTEROL LEVELS AND MARKERS OF INFLAMMATION AND METABOLIC HEALTH IN PATIENTS HOSPITALIZED WITH ACUTE MYOCARDIAL INFARCTION (2010) (0)
Abstract 19075: Impact of LDL Apheresis on Lipoprotein Particle Concentrations (2012) (0)
Role of PAI-1 in hepatic steatosis and dyslipidemia (2021) (0)
Abstract 17189: Indications and Adverse Effects of Statin Therapy in Children: A Retrospective Electronic Medical Record Review (2016) (0)
Abstract 197: Characterization of the Effects of Angiopoietin-Like 3 on Plasma Lipids and Lipoproteins in Humans (2017) (0)
Faculty Opinions recommendation of The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. (2017) (0)
APPLICATION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL POLYGENIC RISK SCORE ANALYSIS IN PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA (2023) (0)
Abstract 14161: Increased Cardiovascular Risk in Patients With Statin-Controlled LDL Cholesterol and Residual Hypertriglyceridemia (2017) (0)
Faculty Opinions recommendation of Association of migraine with aura and other risk factors with incident cardiovascular disease in women. (2020) (0)
CAROTID ADVENTITIAL NEOVASCULARIZATION AND INTIMA–MEDIA THICKNESS AS MARKERS OF ATHEROGENESIS: EVIDENCE FROM TWO RANDOMIZED CONTROLLED TRIALS (2013) (0)
Faculty Opinions recommendation of Time course of LDL cholesterol exposure and cardiovascular disease event risk. (2020) (0)
Abstract: 1007 NEW ONSET DIABETES MELLITUS (DM) IN PATIENTS WITH HYPERLIPIDEMIA (HL) TAKING EZETIMIBE/SIMVASTATIN (E/S) +/− NIACIN (N) (2009) (0)
Editorial Board (2009) (0)
Abstract 312: Enhanced Systemic Inflammation Accelerates Plaque Reduction Following Lipid Lowering Therapy in Mice (2020) (0)
Abstract P071: Association Between Polyunsaturated Fat Consumption and Hypertension among Statin Users and Non-users (2014) (0)
Lipoprotein(a) Gets Worse. (2020) (0)
Long-term Effect of Combination Ezetimibe/Simvastatin+Extended-Release Niacin on Cholesterol Content of Lipoprotein Subclasses in Patients with Hyperlipidemia (2009) (0)
Abstract P100: Identification of Patients with Familial Hypercholesterolemia (FH) Using the Dutch Lipid Network (DLN) Criteria in Electronic Health Records (EHR) (2016) (0)
SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME (2023) (0)
Long-term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin + Extended-Release Niacin in Hyperlipidemic Patients (2009) (0)
Faculty Opinions recommendation of Causal Inference for Genetically Determined Levels of HDL (High-Density Lipoprotein) Cholesterol and Risk of Infectious Disease. (2019) (0)
Faculty of 1000 evaluation for From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. (2018) (0)
Abstract 396: A Unique Case of Artefactual and Real HDL Disappearance Due to Isolevuglandins Adducts (2018) (0)
Faculty of 1000 evaluation for Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycer (2018) (0)
Abstract 632: Modification of HDL by γ-Ketoaldehydes Causes impaired HDL Function in Familial Hypercholesterolemia (2016) (0)
SAFETY AND TOLERABILITY OF THE TRIPLE COMBINATION EZETIMIBE/SIMVASTATIN + EXTENDED RELEASE NIACIN IN HYPERLIPIDEMIA PATIENTS (2008) (0)
RACIAL DIFFERENCES IN THE PREVALENCE OF UNCONTROLLED AND UNREPORTED HYPERTENSION IN THE SOUTHEASTERN UNITED STATES: INSIGHTS FROM ALMOST 70,000 BLACKS AND WHITES IN THE SOUTHERN COMMUNITY COHORT STUDY (2013) (0)
Faculty of 1000 evaluation for Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. (2018) (0)
CORONARY MICROVASCULAR DYSFUNCTION BY MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY IN NON-ELDERLY PATIENTS REFERRED FOR CT CORONARY ANGIOGRAPHY (2019) (0)
Abstract 239: LDL Apheresis Is Associated With a Reduction in Markers of Chronic Inflammation in Patients With Familial Hypercholesterolemia (2014) (0)
Plasma lipid levels and colorectal adenoma risk (2015) (0)
Abstract 10118: PCSK9 Inhibition Augments the Therapeutic Effect of Ezetimibe in Lowering Intestinal Apolipoprotein B Lipoprotein Production (2013) (0)
Circulation Research. (2016) (0)
Quantum Dot - Mediated Imaging of Vascular Disease (2008) (0)
Elevated Levels of Low Density Lipoprotein (LDL) Trigger VWF Self-Association into Fibers and Bundles and Potentiate Microvascular Thrombosis (2022) (0)
Abstract 17184: Achievement Of LDL-cholesterol Reduction Targets is Associated With Reduced Cardiovascular Disease Risk Among Patients With Familial Hypercholesterolemia in a Large Electronic Medical Record Database (2015) (0)
Abstract 479: Expression of ApoE-sendai by Macrophages Causes Lipoprotein Glomerulopathy While Suppressing Atherosclerosis (2013) (0)
Abstract P150: Association of Cholesterol Measures With Coronary Heart Disease Risk in Blacks and Whites in the Reasons for Geographic and Racial Differences in Stroke Study (regards) (2020) (0)
Faculty Opinions recommendation of HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. (2017) (0)
The Apolipoprotein E Cys-142 Mutant: Role in Dominant Inheritance of Type III Hyperlipoproteinemia and Expression in Transgenic Mice (1993) (0)
L1 Tie1 ATTENUATION RESULTS IN A LOCATION-SPECIFIC AND SHEAR STRESS-DEFINED REDUCTION IN ATHEROSCLEROSIS (2010) (0)
Erratum: Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis (2010) (0)
Author response for "Risk of Cardiovascular Events in Patients with Hypertriglyceridemia: A Review of Real‐World Evidence" (2019) (0)
Abstract 19057: Macrophage SR-BI Deletion Promotes Defective Efferocytosis via Src/Akt/Rac1 Signaling Pathway Resulting in Increased Atherosclerotic Lesion Necrosis (2013) (0)
Genetic Data Putting Pleiotropy and Selection Into Context Defines a New Paradigm for Interpreting (2013) (0)
Ezetimibe/Simvastatin + Extended Release Niacin Therapy Improves Attainment of Recommended Levels of LDL-C, Non-HDL-C, and ApoB in Hyperlipidemic Patients† (2011) (0)
Abstract P555: Plasma Lipids And The Risk For Stroke In The Reasons For Geographic And Racial Differences In Stroke Study (regards). (2020) (0)
Faculty Opinions recommendation of Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies. (2019) (0)
Metabolic syndrome predicts adverse cardiovascular risk among the elderly (2005) (0)
PCSK9 inhibition augments the therapeutic effect of ezetimibe in lowering intestinal apolipoprotein B lipoprotein production (2014) (0)
Faculty Opinions recommendation of Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. (2017) (0)
Faculty of 1000 evaluation for APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation and Meta-Analyses of 137 895 Individuals. (2018) (0)
INCREASED MEDICAL CARE COSTS IN PATIENTS WITH STATIN-CONTROLLED LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND RESIDUAL HYPERTRIGLYCERIDEMIA (2018) (0)
[Prevention of cardiovascular diseases]. (1988) (0)
Faculty Opinions recommendation of Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. (2019) (0)
Triple Combination Ezetimibe/Simvas tatin + Extended-Relea se Niacin Therapy Improves Ratios of ApoB/ApoA-I Containing Lipoproteins in Hyperlipidemi a Patients (2008) (0)
byinhibitingfatty-acid-bindingproteinaP2 (2007) (0)
Abstract 123: Reciprocal Regulation of Plasma PCSK9 and Cell-surface Low-density Lipoprotein Receptor (2013) (0)
Is There A Role for Fibrate Therapy in the Management of Dyslipidemia (2015) (0)
Physiological Levels of PCSK9 Promote Hepatic and Intestinal Overproduction of Apolipoprotein-B Lipoproteins Through LDl-Receptor Dependent and Independent Mechanisms (2013) (0)
The American journal of preventive cardiology: On a mission to help define a specialty (2020) (0)
Features of the most commonly used mouse models of dyslipidemia and atherosclerosis (2002) (0)
Faculty Opinions recommendation of Statin therapy increases lipoprotein(a) levels. (2019) (0)
Preventive Cardiology as Specialized Medical Art (2020) (0)
Abstract 29: PCSK9 Association With Lipoprotein(a) (2015) (0)
6-Mercaptopurine, monocytes, and atherosclerosis. (2010) (0)
Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. (2021) (0)
Faculty Opinions recommendation of Inflammasomes in health and disease. (2017) (0)
Relationship Between HsCRP Reduction and LDL-C, Non-HDL-C, ApoB, and HDL-C in Hyperlipidemic Patients Treated with Ezetimibe/Simvastatin + Niaspan† (2011) (0)
Abstract 180: Missense Mutations in ABCA1 and CETP Associate with Changes in the HDL Proteome in Primate Half-Sibs Discordant for HDL Cholesterol Levels (2018) (0)
Faculty Opinions recommendation of Apolipoprotein(a) Kinetics in Statin-Treated Patients with Elevated Plasma Lipoprotein(a) Concentration. (2019) (0)
Polyunsaturated fat intake and mortality in non-statin users, is there an independent relationship? The authors reply. (2016) (0)
Expression of apoESendai by macrophages causes lipoprotein glomerulopathy while suppressing atherosclerosis (2014) (0)
Faculty of 1000 evaluation for Genetic Factors Explain a Major Fraction of the 50% Lower LPA (Lipoprotein[a]) Concentrations in Finns. (2018) (0)
Faculty Opinions recommendation of CAD severity on cardiac CTA identifies patients with most benefit of treating LDL cholesterol to ACC/AHA and ESC/EAS targets. (2020) (0)
Response to Duell et al. (2014) (0)
Faculty Opinions recommendation of Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. (2020) (0)
Inhibition of apolipoprotein(a) synthesis by farnesoid X receptor and fibroblast growth factor 15/19: a step toward selective lipoprotein(a) therapeutics. (2012) (0)
Faculty Opinions recommendation of Cognition After Lowering LDL-Cholesterol With Evolocumab. (2020) (0)
Faculty Opinions recommendation of Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. (2020) (0)
Abstract 15417: Macrophage Deficiency of Akt2 or Both Akt1 and Akt2 Reduces Atherosclerosis: Akt is Critical for Macrophage Polarization and Survival (2013) (0)
Variable responses to a hypercholesterol diet in a group of adult male volunteers (1988) (0)
Response to letter regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms". (2015) (0)
Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review (2022) (0)
TIME AND DOSE-RELATED EFFECTS ON THE LIPID PROFILE IN HYPERLIPIDEMIA PATIENTS FOLLOWING TRIPLE COMBINATION THERAPY WITH EZETIMIBE/SIMVASTATIN + NIACIN (2008) (0)
Result of Genetic Analysis in FH Case (2018) (0)
[The role of fish fats in the prevention of arteriosclerosis]. (1987) (0)
Faculty Opinions recommendation of Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. (2018) (0)
Progress in Cardiovascular (2009) (0)
Faculty Opinions recommendation of Taking One Step Back in Familial Hypercholesterolemia: STAP1 Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans. (2020) (0)
Faculty of 1000 evaluation for Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women. (2018) (0)
Treating the Common Dyslipidemia in Patients with Type 2 Diabetes: Insights from FIELD on the Effects of Fenofibrate on CVD Risk (2006) (0)
Selected for the National Lipid Association 2019 Scientific Sessions , May 16-19 , 2019 , Miami , FL 2019 Program Planners : (2019) (0)
EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED RELEASE NIACIN IN PATIENTS WITH TYPE IIA OR IIB HYPERLIPIDEMIA (2008) (0)
The first mutations of the LDL receptor gene found in Italians (1990) (0)
Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. (2020) (0)
WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. (2018) (0)
Faculty of 1000 evaluation for High-Density Lipoprotein Cholesterol and Mortality: Too Much of a Good Thing? (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sergio Fazio?

Sergio Fazio is affiliated with the following schools: